<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="3-part\PMC7044130\results\search\tropicalVirus\results.xml">
  <result pre="doi: 10.3389/fmicb.2020.00214 : Microbiology: Original Research The Mechanism of the" exact="Zika" post="Virus Crossing the Placental Barrier and the Blood-Brain Barrier"/>
  <result pre="is permitted which does not comply with these terms. Abstract" exact="Zika" post="virus (ZIKV) infection causes severe neurological symptoms in adults"/>
  <result pre="brain of microcephaly and meningoencephalitis patient. However, the mechanism of" exact="ZIKV" post="crossing the physiological barrier to the central nervous systems"/>
  <result pre="in vitro models of the physiological barriers. Results showed that" exact="ZIKV" post="could infect JEG-3 cells effectively and reduce the amounts"/>
  <result pre="the permeability of the barrier differentially changed in response to" exact="ZIKV" post="infection, allowing the virus particle to cross the host"/>
  <result pre="the virus particle to cross the host barrier. In contrast," exact="ZIKV" post="could infect hCMEC/D3 cells without disrupting the BBB barrier"/>
  <result pre="expression. Although no disruption to the BBB was observed during" exact="ZIKV" post="infection, ZIKV particles were released on the basal side"/>
  <result pre="no disruption to the BBB was observed during ZIKV infection," exact="ZIKV" post="particles were released on the basal side of the"/>
  <result pre="and infected underlying cells. In addition, we observed that fluorescence-labeled" exact="ZIKV" post="particles could cross the in vitro placenta barrier and"/>
  <result pre="low temperature or pharmacological inhibitors of endocytosis. In summary, the" exact="ZIKV" post="uses a cell-type specific paracellular pathway to cross the"/>
  <result pre="monolayer barrier by disrupting cellular tight junction. In addition, the" exact="ZIKV" post="can also cross both the placenta barrier and the"/>
  <result pre="into on the mechanism of the cellular barrier penetration of" exact="ZIKV" post="particles. Zika virus placental barrier blood-brain barrier tight junction"/>
  <result pre="the mechanism of the cellular barrier penetration of ZIKV particles." exact="Zika" post="virus placental barrier blood-brain barrier tight junction transcytosis single-virus"/>
  <result pre="ZO-1 Occludin fig-count: table-count: equation-count: ref-count: page-count: word-count: Introduction The" exact="Zika" post="virus (ZIKV), first isolated from the rhesus monkey in"/>
  <result pre="Flaviviridae family, which also include the dengue virus (DENV), the" exact="West Nile" post="virus (WNV), the Japanese encephalitis viruses (JEV) and the"/>
  <result pre="(JEV) and the yellow fever virus (YFV). Until 2015, most" exact="ZIKV" post="infections were deemed as a mild illness with some"/>
  <result pre="conjunctivitis (Petersen et al., 2016). However, based on recent epidemics," exact="ZIKV" post="infection in adult is associated with the Guillain-Barre’ syndrome"/>
  <result pre="al., 2016; Soares et al., 2016). Moreover, vertical transmission of" exact="ZIKV" post="from mother to fetus is linked to the elevating"/>
  <result pre="fetus is linked to the elevating incidences of the congenital" exact="Zika" post="syndrome on fetuses including microcephaly, congenital malformation, and fetal"/>
  <result pre="2018). For those infants born with a normal head, congenital" exact="ZIKV" post="infection may also cause developed postnatal-onset microcephaly, joint disorders,"/>
  <result pre="2018). These studies revealed a wide-spectrum of effects that congenital" exact="ZIKV" post="infection has on fetuses, strongly suggesting the importance of"/>
  <result pre="transmission. To reach the fetus brain from the infected mother," exact="ZIKV" post="needs to pass two major physiological barriers, the placenta"/>
  <result pre="recent studies reported that no barrier disruption was observed when" exact="ZIKV" post="gained access to the CNS (Papa et al., 2017;"/>
  <result pre="suggesting that the endocytic transport system is required for the" exact="ZIKV" post="to cross the BBB barrier. Given the existence of"/>
  <result pre="limit pathogen paracellular movement under the normal condition. However, the" exact="ZIKV" post="could be detected in the brains of microcephalic infants,"/>
  <result pre="detected in the brains of microcephalic infants, suggesting that the" exact="ZIKV" post="can penetrate the CNS in fetus (Calvet et al.,"/>
  <result pre="cytomegalovirus (CMV), the Human immunodeficiency virus type 1 (HIV-1), the" exact="West Nile" post="virus (WNV), the Japanese encephalitis virus (JEV), and herpes"/>
  <result pre="through the paracellular pathway but also through transcytosis. Although the" exact="ZIKV" post="is detected in both the amniotic fluid of pregnant"/>
  <result pre="single-virus tracking (SVT) approach to elucidate the mechanism that the" exact="ZIKV" post="employs to cross the placental and the BBB barriers."/>
  <result pre="penicillin/streptomycin. All cells were incubated at 37°C with 5% CO2." exact="ZIKV" post="Amplification The ZIKV strain PRVABC59 (2015 Puerto Rico strain,"/>
  <result pre="were incubated at 37°C with 5% CO2. ZIKV Amplification The" exact="ZIKV" post="strain PRVABC59 (2015 Puerto Rico strain, GenBank accession: KU501215)"/>
  <result pre="was propagated in Vero E6 cells. Cells were exposed to" exact="ZIKV" post="with multiplicity of infection (MOI) of 0.02 in a"/>
  <result pre="ZIKV-containing supernatant was stored at −80°C. Immunofluorescence Microscopy Imaging For" exact="ZIKV" post="infection assays, JEG-3 and hCMEC/D3 cells were seeded on"/>
  <result pre="by 0.1% Triton X-100 in PBS. The expression of the" exact="ZIKV" post="E protein was recognized by a 1:100 diluted rabbit"/>
  <result pre="vitro Transwell Barrier Assay To assess the ability of the" exact="ZIKV" post="crossing the barrier in vitro, the virus was added"/>
  <result pre="Transwell insert after the barrier cells were exposed to the" exact="ZIKV" post="for 24 h. The cells were seeded on the"/>
  <result pre="Reverse: 5′- CTCTAGGTGCCTGTTCGTAACGT-3′), Occludin (Forward: 5′- TCAGGGAATATCCACCTATCACTTCAG-3′; Reverse: 5′- CATCAGCAGCAGCCATGTACTCTTCAC-3′)," exact="ZIKV" post="E protein (Forward: 5′- AAGTACACATACCAAAACAAAGTGGT-3′; Reverse: 5′- TCCGCTCCCCCTTTGGTCTTG-3′), and"/>
  <result pre="at 95°C and 30 s at 60°C. Preparation of Fluorescence-Labeled" exact="ZIKV" post="Particles The procedure of virus labeling was performed as"/>
  <result pre="previously described with minor modifications (Chu et al., 2014, 2019)." exact="ZIKV" post="particles were pelleted from a ZIKV-containing supernatant by ultra-centrifugation"/>
  <result pre="and further concentrated by ultrafiltration spin columns (GE healthcare). Concentrated" exact="ZIKV" post="particles were labeled with Atto647N-NHS ester (Sigma-Aldrich), with maximum"/>
  <result pre="maximum emission at 664 nm. Briefly, 1 × 107pfu/ml of" exact="ZIKV" post="were mixed with 2 nmol of Atto 647N NHS"/>
  <result pre="at room temperature. The unincorporated dye was separated from fluorescence-labeled" exact="ZIKV" post="particles by a Sephadex G-25 column (GE Healthcare). The"/>
  <result pre="a Sephadex G-25 column (GE Healthcare). The fractions containing Atto647N-labeling" exact="ZIKV" post="were detected by a multimode microplate reader (TECAN 200/200Pro)"/>
  <result pre="PBS and were infected with 10-fold serial dilutions of the" exact="ZIKV" post="at 37°C with 5% CO2 for 2 h. Afterward,"/>
  <result pre="∗∗p &amp;lt; 0.01, ∗∗∗p &amp;lt; 0.001, ****p &amp;lt; 0.0001. Results" exact="ZIKV" post="Infects Both JEG-3 Cells and hCMEC/D3 Cells With No"/>
  <result pre="Effect on Cell Viability To investigate the mechanism of the" exact="ZIKV" post="crossing the placental barrier and the BBB, we infected"/>
  <result pre="et al., 2017). To first clarify the infectivity of the" exact="ZIKV" post="in JEG-3 and hCMEC/D3 cells, the viral envelop (E)"/>
  <result pre="anti-ZIKV E protein antibody at 24 h post-infection. Apparently, the" exact="ZIKV" post="E protein was detected in both cell lines in"/>
  <result pre="cells could be elevated as MOI increased (Figure 1B). The" exact="ZIKV" post="infected more than 80% cells at a MOI of"/>
  <result pre="post-infection (Figure 1C). FIGURE 1 The infectivity and virulence of" exact="ZIKV" post="in JEG-3 and hCMEC/D3 cells. (A) The immunofluorescence images"/>
  <result pre="in JEG-3 and hCMEC/D3 cells. (A) The immunofluorescence images of" exact="ZIKV" post="E protein revealed the population of ZIKV-infected cells in"/>
  <result pre="(MOI of 1 to 10) at 24 h post-infection. The" exact="ZIKV" post="E protein antibody was recognized by an Alex488-secondary antibody"/>
  <result pre="cells was quantified from (A). (C) JEG-3 cells were infected" exact="ZIKV" post="at MOI of 0.5 to 1, and hCMEC/D3 cells"/>
  <result pre="MOI of 0.5 to 1, and hCMEC/D3 cells were infected" exact="ZIKV" post="at MOI of 5 to 10 during 24 h."/>
  <result pre="of 5 to 10 during 24 h. The virulence of" exact="ZIKV" post="in JEG-3 and hCMEC/D3 was measured by a cell"/>
  <result pre="were obtained through t-tests. **p &amp;lt; 0.01; ***p &amp;lt; 0.001." exact="ZIKV" post="Crosses an In vitro Human Physiological Barrier Model Next,"/>
  <result pre="an in vitro Transwell barrier assay to investigate whether the" exact="ZIKV" post="can cross barrier cells. As shown in Figure 2A,"/>
  <result pre="plate containing pre-seed adherent Vero cells in the basal chamber." exact="ZIKV" post="was added on the top of the inserts at"/>
  <result pre="top of the inserts at a MOI of 0.5. If" exact="ZIKV" post="particles could cross barrier cells, they would exist in"/>
  <result pre="chamber and infect into Vero cells. The existence of the" exact="ZIKV" post="in Vero cells was detected by immunostaining using an"/>
  <result pre="anti-ZIKV E protein antibody. The results showed clearly that the" exact="ZIKV" post="E protein could be detected in Vero cells in"/>
  <result pre="as barrier cells (Figure 2B). These results indicated that the" exact="ZIKV" post="could cross the human physiological barrier cells. It is"/>
  <result pre="the human physiological barrier cells. It is possible for the" exact="ZIKV" post="to cross barrier cells by altering the permeability of"/>
  <result pre="added in the apical chamber after 24 h post-infection. If" exact="ZIKV" post="infection could alter cell permeability, the signal of FITC-dextran"/>
  <result pre="detected in the basal chamber. Compared with the mock group," exact="ZIKV" post="infection did increase FITC-dextran signal significantly when JEG-3 cells"/>
  <result pre="used as a positive control. These results suggested that the" exact="ZIKV" post="may cross the placenta barrier by changing the permeability"/>
  <result pre="changing the permeability of the barrier cells. In contrast, the" exact="ZIKV" post="crosses the BBB barrier cells but does not change"/>
  <result pre="barrier cells (Figures 2B,C), suggesting no barrier leakage when the" exact="ZIKV" post="crossed the BBB. FIGURE 2 ZIKV crossed in vitro"/>
  <result pre="barrier leakage when the ZIKV crossed the BBB. FIGURE 2" exact="ZIKV" post="crossed in vitro human physiological barriers. (A) A schematic"/>
  <result pre="in vitro barrier cells. (B) The immunofluorescence images of the" exact="ZIKV" post="E protein revealed ZIKV-infected Vero cells cultured in a"/>
  <result pre="barrier at MOI of 10 at 24 h post-infection. The" exact="ZIKV" post="E protein antibody was recognized by an Alex488-secondary antibody"/>
  <result pre="control. The permeability of an hCMEC/D3 barrier at 24 h" exact="ZIKV" post="post-infection was measured in (D). The error bars represent"/>
  <result pre="experiments. *p &amp;lt; 0.05; **p &amp;lt; 0.01; ****p &amp;lt; 0.0001." exact="ZIKV" post="Down-Regulated the Expression of Tight Junction Protein Through a"/>
  <result pre="Pathway Given that the leakage of FITC-dextran was increased by" exact="ZIKV" post="infection in the in vitro placenta barrier model but"/>
  <result pre="ZO-1 and occludin in JEG-3 cells in the presence of" exact="ZIKV" post="infection compared to that in the mock control group"/>
  <result pre="3B). To further confirm the disruption of tight junction by" exact="ZIKV" post="infection in JEG-3 cells, the distribution of ZO-1 and"/>
  <result pre="formed continuous seals between adjacent cells in the absence of" exact="ZIKV" post="infection (Figure 3C). In contrast, ZIKV infection disrupted the"/>
  <result pre="in the absence of ZIKV infection (Figure 3C). In contrast," exact="ZIKV" post="infection disrupted the continuity of occludin and ZO-1 in"/>
  <result pre="measuring the branch length of segments. The results demonstrated that" exact="ZIKV" post="infection declined the integrity of tight junction of JEG-3"/>
  <result pre="junction of JEG-3 cells (Figure 3C, right panel). FIGURE 3" exact="ZIKV" post="infection decreased expression of the tight junction protein ZO-1"/>
  <result pre="ZO-1 and Occludin were not affected in hCMEC/D3 cells with" exact="ZIKV" post="infection. The amount of ZO-1 and Occludin was normalized"/>
  <result pre="The distribution of ZO-1 and Occludin in JEG-3 cells with/without" exact="ZIKV" post="infection were imaged by confocal microscopy. The white arrows"/>
  <result pre="JEG-3 and hCMEC/D3 cells in the absence or presence of" exact="ZIKV" post="infection were determined by RT-qPCR. The results of RT-qPCR"/>
  <result pre="and occludin in both JEG-3 and hCMEC/D3 cells regardless of" exact="ZIKV" post="infection (Figures 4A,B). These data suggested that the down"/>
  <result pre="at the post-transcription level. To confirm this speculation, prior to" exact="ZIKV" post="infection, JEG-3 cells were treated individually by a series"/>
  <result pre="Figure 4C, the expression of ZO-1 and occludin repressed by" exact="ZIKV" post="infection could be notably rescued only by MG132, a"/>
  <result pre="of autophagosomes and lysosomes. Taken together, these results demonstrated that" exact="ZIKV" post="infection causes the leakage of the placenta barrier through"/>
  <result pre="cellular tight junction via the proteasomal degradation pathway. FIGURE 4" exact="ZIKV" post="infection decreased the accumulation of tight junction proteins through"/>
  <result pre="levels of ZO-1, Occludin and ZIKV-E in JEG-3 cells upon" exact="ZIKV" post="infection were quantified by RT-qPCR. Data were normalized by"/>
  <result pre="mRNA levels of ZO-1, Occludin and ZIKV-E in hCMEC/D3 upon" exact="ZIKV" post="infection are shown in (B). The error bars represent"/>
  <result pre="and Occludin in JEG-3 cells with various inhibitors treatments upon" exact="ZIKV" post="infection. The amount of ZO-1 and Occludin was normalized"/>
  <result pre="three independent experiments. *p &amp;lt; 0.05. Visualization of Transcytosis of" exact="ZIKV" post="It has been reported that transcytosis, a series action"/>
  <result pre="like to conduct a single-virus imaging analysis to investigate whether" exact="ZIKV" post="particle can also cross barriers cells by transcytosis in"/>
  <result pre="transcytosis in in vitro Transwell barrier models. To visualize single" exact="ZIKV" post="particles directly, ZIKV particles were labeled with a fluorescence"/>
  <result pre="vitro Transwell barrier models. To visualize single ZIKV particles directly," exact="ZIKV" post="particles were labeled with a fluorescence dye, atto647N, by"/>
  <result pre="the amino group of the viral envelope protein. The atto647N-labeled" exact="ZIKV" post="particles were purified through a Sephadex G-25 size-exclusion column."/>
  <result pre="6 to Fraction 10 (Figure 5A, solid squares) indicated atto647N-labeled" exact="ZIKV" post="particles (atto647N-ZIKV) because the diameter of a single ZIKV"/>
  <result pre="atto647N-labeled ZIKV particles (atto647N-ZIKV) because the diameter of a single" exact="ZIKV" post="particle is approximately 50 nm (Sirohi et al., 2016;"/>
  <result pre="detected within the same range of fractions from the Dye-free" exact="ZIKV" post="group (Figure 5A, solid triangles). These results confirmed a"/>
  <result pre="5A, solid triangles). These results confirmed a successful conjugation of" exact="ZIKV" post="particles with atto647N. The infectivity of atto647N-ZIKV particles was"/>
  <result pre="particles was then measured by a plaque assay. Both dye-free" exact="ZIKV" post="and atto647N-ZIKV presented similar virus titers, suggesting no significant"/>
  <result pre="atto647N-ZIKV presented similar virus titers, suggesting no significant influence on" exact="ZIKV" post="infectivity by the atto647N labeling procedure (Figure 5B). FIGURE"/>
  <result pre="the atto647N labeling procedure (Figure 5B). FIGURE 5 Detection of" exact="ZIKV" post="transcytosis. (A) Fluorescence intensity profiles of elution from a"/>
  <result pre="filtration (solid squares). No fluorescence signal was detected in Atto647N-free" exact="ZIKV" post="(solid triangles) within the same fraction layers. The 40"/>
  <result pre="were performed to determine the infectivity of the Atto647N-ZIKV. Dye-free" exact="ZIKV" post="was used as a control. Both virus samples were"/>
  <result pre="Transwell barrier assay, we would like to investigate whether the" exact="ZIKV" post="can penetrate a monolayer of barrier cells at 4°C"/>
  <result pre="4°C and 37°C (Figure 5D). These results implied that the" exact="ZIKV" post="can cross monolayers of either JEG-3 or hCMEC/D3 cells"/>
  <result pre="through a temperature-dependent transcytosis. To directly visualize the transcytosis of" exact="ZIKV" post="particle across a monolayer of barrier cells, we infected"/>
  <result pre="observed in hCMEC/D3 monolayers (Figure 6B). These results elucidated that" exact="ZIKV" post="particles might be directly transported across the monolayer of"/>
  <result pre="without undergoing the viral replication process. FIGURE 6 Visualization of" exact="ZIKV" post="transcytosis. The ZX images of confocal microscopy depicted the"/>
  <result pre="A), and cell membrane was stained by WGA488 (green) (A,B)." exact="ZIKV" post="Transport Can Be Blocked by Endocytosis and Microtubule Inhibitors"/>
  <result pre="vesicle-mediated endocytosis and macropinocytosis. To further examine endocytic pathways for" exact="ZIKV" post="entrance into barrier cells, we pretreated barrier cells with"/>
  <result pre="(Figure 7C), suggesting that endocytosis might be essential for the" exact="ZIKV" post="to cross the monolayer of barrier cells. In addition,"/>
  <result pre="ZIKV. To further quantify the effect of inhibitors on the" exact="ZIKV" post="crossing barrier cells, the titers of ZIKV isolated from"/>
  <result pre="inhibitors on the ZIKV crossing barrier cells, the titers of" exact="ZIKV" post="isolated from the basal chamber 3 h post-infection were"/>
  <result pre="suggested that transcytosis may be an important pathway for the" exact="ZIKV" post="to cross the placental barrier and the BBB. FIGURE"/>
  <result pre="to cross the placental barrier and the BBB. FIGURE 7" exact="ZIKV" post="transcytosis across JEG-3 and hCMEC/D3 barriers can be reduced"/>
  <result pre="Discussion In this study we investigated the pathways for the" exact="ZIKV" post="crossing the endothelial cell monolayer of both the placenta"/>
  <result pre="Using fluorescence-tagged dextran as an indicator, our results revealed that" exact="ZIKV" post="infection enhanced cellular permeability in JEG-3 cells but not"/>
  <result pre="cells but not in hCMEC/D3 cells. Moreover, in JEG-3 cells," exact="ZIKV" post="infection reduces the amount of tight junction proteins, ZO-1"/>
  <result pre="resulting in disruption of tight junction. In contrast, using fluorescence-labeled" exact="ZIKV" post="particles and pharmacological inhibitors of endocytosis, we demonstrated transcytosis"/>
  <result pre="endocytosis, we demonstrated transcytosis as an additional pathway for the" exact="ZIKV" post="crossing the monolayer of JEG-3 and hCMEC/D3. As summarized"/>
  <result pre="summarized in Figure 8, our current study elucidated that the" exact="ZIKV" post="uses a cell-type specific paracellular pathway to cross the"/>
  <result pre="monolayer barrier by disrupting cellular tight junction. In addition, the" exact="ZIKV" post="can also cross both the placenta barrier and the"/>
  <result pre="present study provides new insights on cellular barrier penetration of" exact="ZIKV" post="particles, which may facilitate the development of anti-ZIKV agents"/>
  <result pre="FIGURE 8 A schematic diagram depicts the mechanism of the" exact="ZIKV" post="crossing human physiological barriers. In the placenta barrier, ZIKV"/>
  <result pre="the ZIKV crossing human physiological barriers. In the placenta barrier," exact="ZIKV" post="infection can lead to disruption of tight junction that"/>
  <result pre="lead to disruption of tight junction that results in the" exact="ZIKV" post="crossing through the leakage of tight junction. In addition,"/>
  <result pre="crossing through the leakage of tight junction. In addition, the" exact="ZIKV" post="can also transport from the apical side to the"/>
  <result pre="the transcytosis pathway (top panel). In the blood-brain barrier, the" exact="ZIKV" post="can transport from the apical side to the basolateral"/>
  <result pre="(bottom panel). Several lines of evidence showed the existence of" exact="ZIKV" post="antigens in the chronic villi of a human placenta"/>
  <result pre="infant with microcephaly (Calvet et al., 2016), and isolation of" exact="ZIKV" post="RNA from placental tissue of mice infected with the"/>
  <result pre="ZIKV RNA from placental tissue of mice infected with the" exact="ZIKV" post="(Caine et al., 2018), suggesting that the ZIKV may"/>
  <result pre="with the ZIKV (Caine et al., 2018), suggesting that the" exact="ZIKV" post="may penetrate the placental barrier to infect the infant"/>
  <result pre="to infect the infant brain. Recent studies reported that the" exact="ZIKV" post="is able to infect and replicate in Hofbauer cells"/>
  <result pre="in cytotrophoblasts, suggesting a route of intrauterine transmission that the" exact="ZIKV" post="crosses the fetal compartment by directly infecting the placental"/>
  <result pre="et al., 2016). In this study, we revealed that the" exact="ZIKV" post="could cross the placenta barrier with both paracellular and"/>
  <result pre="respectively (Mateo et al., 2015). However, our data revealed that" exact="ZIKV" post="infection causes leakage of the placental barrier by disrupting"/>
  <result pre="al., 2016), our results proposed a paracellular pathway for the" exact="ZIKV" post="crossing the placental barrier by disrupting the cellular tight"/>
  <result pre="occludin. The activation mechanism of the proteasomal degradation pathway by" exact="ZIKV" post="infection remains to be further investigated. Using a SVT"/>
  <result pre="a SVT approach, we provided evidence to elucidate that the" exact="ZIKV" post="can cross the in vitro placenta model through transcytosis"/>
  <result pre="Story, 1997; Palmeira et al., 2012), Matthew al. showed that" exact="DENV" post="cross-reactive mAbs bound to the ZIKV undergo FcRn-mediated transcytosis"/>
  <result pre="Matthew al. showed that DENV cross-reactive mAbs bound to the" exact="ZIKV" post="undergo FcRn-mediated transcytosis across the placenta to productively infect"/>
  <result pre="macrophages (Zimmerman et al., 2018). In the current study, the" exact="ZIKV" post="crossing the placenta barrier cells was directly visualized by"/>
  <result pre="newly produced viral particles after replication. Moreover, the action of" exact="ZIKV" post="transcytosis could be inhibited by treatments with endocytosis inhibitors"/>
  <result pre="the paracellular pathway and the transcytosis pathway are utilized by" exact="ZIKV" post="to cross the placenta barrier (Figure 8, top panel)."/>
  <result pre="Further studies will be needed in order to illustrate how" exact="ZIKV" post="particles select a pathway to cross the placenta barrier"/>
  <result pre="placenta barrier and whether they require a specific receptor for" exact="ZIKV" post="to interact with. In addition to the placenta barrier,"/>
  <result pre="transcytosis (Mustafa et al., 2019). In the current study, the" exact="ZIKV" post="can cross brain endothelial cells and release of infectious"/>
  <result pre="7). This is in agreement with previous studies showing the" exact="ZIKV" post="crosses the BBB monolayer without the BBB barrier disruption"/>
  <result pre="permeability. Furthermore, although in vivo experiment models proposed that the" exact="ZIKV" post="crosses the BBB with no severe disruption, barrier breakdown"/>
  <result pre="at a later post-infection time (Papa et al., 2017). Because" exact="ZIKV" post="infection may recruit leukocyte to the brain and induce"/>
  <result pre="response rather than ZIKV-induced proteasomal degradation. Understanding the pathways for" exact="ZIKV" post="passing through physiological barriers, the placental barrier and the"/>
  <result pre="the BBB, furthers our understanding of the pathophysiology of the" exact="ZIKV" post="and provides a basis for developing anti-ZIKV drugs in"/>
  <result pre="in a paracellular pathway for the maternal-fetal transmission of the" exact="ZIKV" post="by disrupting tight junction proteins (Figures 2–4), it may"/>
  <result pre="evidence that transcytosis may be a common strategy for the" exact="ZIKV" post="to cross both the placental barrier and the BBB"/>
  <result pre="it may not be a good druggable target to treat" exact="ZIKV" post="infection. Therefore, further studies to reveal whether there is"/>
  <result pre="to reveal whether there is a specific interaction of the" exact="ZIKV" post="with the transcytosis machine will facilitate the development of"/>
  <result pre="(108DN01) to Y-HP. We are thankful to Taiwan CDC for" exact="Zika" post="virus (PRVABC59 strains). We also thank Dr. Janice Fon"/>
  <result pre="editing this article. References References AlimontiJ. B.Ribecco-LutkiewiczM.SodjaC.JezierskiA.StanimirovicD. B.LiuQ.et al. (2018)." exact="Zika" post="virus crosses an in vitro human blood brain barrier"/>
  <result pre="E.CalvetG. A.De SouzaR. V.et al. (2016). Guillain-Barre syndrome associated with" exact="Zika" post="virus infection.Lancet387:1482. BurtonG. J.FowdenA. L. (2015). The placenta: a"/>
  <result pre="S. O.SampaioS. A.De FilippisI.FabriA.et al. (2016). Detection and sequencing of" exact="Zika" post="virus from amniotic fluid of fetuses with microcephaly in"/>
  <result pre="al. (2014). Single-virus tracking approach to reveal the interaction of" exact="Dengue" post="virus with autophagy during the early stage of infection.J."/>
  <result pre="CordeiroM. T.PenaL. J.BritoC. A.GilL. H.MarquesE. T. (2016). Positive IgM for" exact="Zika" post="virus in the cerebrospinal fluid of 30 neonates with"/>
  <result pre="neonates with microcephaly in Brazil.Lancet3871811–1812. 10.1016/s0140-6736(16)30253-7 CoyneC. B.LazearH. M. (2016)." exact="Zika" post="virus - reigniting the TORCH.Nat. Rev. Microbiol.14707–715. 10.1038/nrmicro.2016.12527573577 DanemanR.PratA."/>
  <result pre="viral infections.Annu. Rev. Virol.1133–146. 10.1146/annurev-virology-031413-08552426958718 DickG. W.KitchenS. F.HaddowA. J. (1952)." exact="Zika" post="virus. i. isolations and serological specificity.Trans. R. Soc. Trop."/>
  <result pre="Trop. Med. Hyg.46509–520. 10.1016/0035-9203(52)90042-412995440 Dos SantosT.RodriguezA.AlmironM.SanhuezaA.RamonP.De OliveiraW. K.et al. (2016)." exact="Zika" post="virus and the guillain-barre syndrome - case series from"/>
  <result pre="Biophys. Acta1778660–669. 10.1016/j.bbamem.2007.07.01217854762 HoenB.SchaubB.FunkA. L.ArdillonV.BoullardM.CabieA.et al. (2018). Pregnancy outcomes after" exact="ZIKV" post="infection in french territories in the americas.N. Engl. J."/>
  <result pre="components.J. Cell Sci.128431–439. 10.1242/jcs.15940026046138 MittalR.NguyenD.DebsL. H.PatelA. P.LiuG.JhaveriV. M.et al. (2017)." exact="Zika" post="virus: an emerging global health threat.Front. Cell Infect. Microbiol.7:486."/>
  <result pre="global health threat.Front. Cell Infect. Microbiol.7:486. 10.3389/fcimb.2017.0048629276699 MlakarJ.KorvaM.TulN.PopovicM.Poljsak-PrijateljM.MrazJ.et al. (2016)." exact="Zika" post="virus associated with microcephaly.N. Engl. J. Med.374951–958. 10.1056/NEJMoa160065126862926 MoradG.CarmanC."/>
  <result pre="P.MeurenL. M.CoelhoS. V. A.LucasC. G. O.MustafaY. M.Lemos MatassoliF.et al. (2017)." exact="Zika" post="virus infects, activates, and crosses brain microvascular endothelial cells,"/>
  <result pre="barrier disruption.Front. Microbiol.8:2557. 10.3389/fmicb.2017.0255729312238 PetersenL. R.JamiesonD. J.PowersA. M.HoneinM. A. (2016)." exact="Zika" post="virus.N. Engl. J. Med.3741552–1563.27028561 QuickeK. M.BowenJ. R.JohnsonE. L.McdonaldC. E.MaH.O’NealJ."/>
  <result pre="J. Med.3741552–1563.27028561 QuickeK. M.BowenJ. R.JohnsonE. L.McdonaldC. E.MaH.O’NealJ. T.et al. (2016)." exact="Zika" post="virus infects human placental macrophages.Cell Host Microbe2083–90. 10.1016/j.chom.2016.05.01527247001 RoeK.KumarM.LumS.OrilloB.NerurkarV."/>
  <result pre="G.et al. (2016). The 3.8 A resolution cryo-EM structure of" exact="Zika" post="virus.Science352467–470. 10.1126/science.aaf531627033547 SoaresC. N.BrasilP.CarreraR. M.SequeiraP.De FilippisA. B.BorgesV. A.et al."/>
  <result pre="M.SequeiraP.De FilippisA. B.BorgesV. A.et al. (2016). Fatal encephalitis associated with" exact="Zika" post="virus infection in an adult.J. Clin. Virol.8363–65. 10.1016/j.jcv.2016.08.29727598870 StamatovicS."/>
 </snippets>
</snippetsTree>
